Letters to the Editor

CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia

Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192, China; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 311121
Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192, China; School of Medicine, Nankai University, Tianjin, 300071
Institute of Ocean Research, Ningbo Institute of Marine Medicine, Peking University, Beijing, 100191
Xiamen Nuokangde Biological Technology Co., Ltd, Xiamen, 361006
Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192
Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192
Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192
Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192
Xiamen Nuokangde Biological Technology Co., Ltd, Xiamen, 361006
State Key Laboratory of Medicinal Chemical Biology and College of Life Science, Nankai University, Tianjin, 300350
Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361102
Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016
Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192, China; School of Medicine, Nankai University, Tianjin, 300071
Haematologica Early view May 2, 2024 https://doi.org/10.3324/haematol.2023.284241